Cassava Sciences | PTIE - Current Assets


Cassava Sciences reported $108.91M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Abbott USD 24.84B 371M Sep/2025
Amgen USD 27.88B 1.15B Sep/2025
Biogen USD 8.94B 968.9M Sep/2025
Cassava Sciences USD 108.91M 5.91M Sep/2025
Eisai JPY 790.7B 27.55B Sep/2025
Eli Lilly USD 62.07B 12.22B Sep/2025
Geron USD 522.34M 16.75M Sep/2025
J&J USD 54.61B 113M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025